Recent events
Recent events tied to this brand in public sources.
Back to profile7 entries
2021
Anteris partners with IQVIA and CRF for FDA feasibility study
Anteris Technologies partnered with IQVIA and the Cardiovascular Research Foundation to help conduct an FDA early feasibility study of its DurAVR THV System.
2021
IQVIA Biotech launches in Japan and Asia Pacific
IQVIA announced the expansion of IQVIA Biotech, its integrated clinical and commercial solutions offering for biotech and emerging biopharma companies, into Japan and Asia Pacific.
2021
IQVIA acquires Quest Diagnostics’ Q2 Solutions stake
IQVIA acquired Quest Diagnostics’ 40 percent minority share of Q2 Solutions for $760 million, resulting in IQVIA owning 100 percent. Quest Diagnostics was to remain Q2 Solutions clients’ strategic preferred laboratory provider under a multi-year agreement.
2020
IQVIA revises 2020 guidance
IQVIA said it now expects full-year 2020 revenue of $10.60 billion to $10.925 billion, adjusted EBITDA of $2.20 billion to $2.30 billion, and adjusted earnings per share of $5.75 to $6.10. The guidance includes the estimated impact of general business disruption caused by COVID-19.
2020
IQVIA launches FluSTAR mobile app
IQVIA announced the launch of FluSTAR, a mobile application providing current flu and cold information to help consumers understand and track illness severity.
2019
BC Platforms closes $15 million Series C financing
BC Platforms announced that it had closed a USD $15 million financing round led by IQVIA alongside Debiopharm Innovation Fund and Tesi.
2019
BC Platforms and IQVIA announce genomics analytics collaboration
BC Platforms and IQVIA announced a commercial collaboration to combine their technologies and data capabilities. The companies plan to launch data-driven technologies integrating clinical and genomic data.